- Campbell's Soup CEO: 'I Have Never Seen Industry Conditions Like Today'
- Want to Know the Real Problem With the U.S. Economy?
- Tesla Tanks as GE Eyes Energy Storage Role, Baidu Plunges on Weak Forecast
- I Got a Perfect Credit Score: Here's How You Can Do It, Too
- MannKind Relies on 'Death Spiral' Financing to Help Settle Looming Debt
Allergan (AGN) was the best performer on the S&P 500 Monday after Teva Pharmaceuticals (TEVA) agreed to buy its generic-drug business for more than $40 billion.
Jim Cramer is watching Twitter (TWTR) as the social media giant releases earnings for its second quarter on Tuesday, July 28th after the market’s closing bell.
CNBC’s ‘Fast Money’ traders take a closer look at U.S. stocks, as the selloff in China weighs on the market.
Teva Pharmaceutical Industries Ltd. (TEVA) announced on Monday that it would acquire the generics business of Allergan plc (AGN) for $40.5 billion.
Investor confidence in biotech stocks is shaky following last week's Biogen blow-up, making Tuesday's Gilead earnings even more important.
U.S.-listed Chinese stocks were under pressure after China's stock market fell at the fastest pace since 2007 on Monday.
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
After cutting its revenue growth forecast, will Biogen buy itself back into investors' good graces?
U.S. stock futures are dropping as sinking Asian and European stocks weighed on markets, despite a big deal in health care between Teva Pharmaceutical and Allergan.
The CNBC "Fast Money" traders look at recent earnings and consider whether dips in stock and oil prices present opportunities for investors.
More earnings and new phones from Motorola are also on the list of what to watch.
TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Shares of home health and hospice care provider Amedisys are up over 50% so far in 2015.
Anthem (WLP) has made it official. It's buying Cigna (CI) for $54.2 billion, creating a health insurance giant.
U.S. stock futures are rising as investors look to manufacturing data and await a morning rush of earnings reports.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV